Regeneron touts Eylea strength as Novartis rival falters, COVID-19 cuts demand

[cafead]

via At the beginning of 2020, Regeneron was in defense mode, scrambling to protect its top-selling Eylea against Novartis’ newly launched Beovu. Now, the company has quickly seized the opportunity presented by a safety flag for its new rival.

article source